Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)
China
· Delayed Price · Currency is CNY 12.42
+0.18 (1.47%)
Mar 10, 2026, 3:04 PM CST
SHE:301211 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Operating Revenue | 422.66 | 437.76 | 651.42 | 511.65 | 539.75 | 592.36 | Upgrade
|
| Other Revenue | 8.11 | 8.11 | 11.61 | 3.26 | 0.87 | 0.57 | Upgrade
|
| Revenue | 430.77 | 445.86 | 663.03 | 514.91 | 540.62 | 592.92 | Upgrade
|
| Revenue Growth (YoY) | -5.24% | -32.75% | 28.77% | -4.76% | -8.82% | -10.17% | Upgrade
|
| Cost of Revenue | 338.18 | 317.79 | 397.55 | 369.78 | 358.33 | 298.54 | Upgrade
|
| Gross Profit | 92.59 | 128.07 | 265.47 | 145.13 | 182.3 | 294.38 | Upgrade
|
| Selling, General & Admin | 65.19 | 61.71 | 62.09 | 47.9 | 38.54 | 67.77 | Upgrade
|
| Research & Development | 26.87 | 32.94 | 52.77 | 19.84 | 18.28 | 22.98 | Upgrade
|
| Other Operating Expenses | 3.84 | 3.77 | 5.92 | 3.96 | 5.89 | 3.15 | Upgrade
|
| Operating Expenses | 94.85 | 98.44 | 120.07 | 69.78 | 64.23 | 94.33 | Upgrade
|
| Operating Income | -2.26 | 29.64 | 145.4 | 75.35 | 118.06 | 200.05 | Upgrade
|
| Interest Expense | -0.26 | -0.31 | -0.31 | -0.34 | - | -2.28 | Upgrade
|
| Interest & Investment Income | 20.7 | 51.33 | 47.84 | 61.02 | 13.1 | 9.05 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.34 | 3.34 | 3.36 | 4.78 | -3.62 | -10.44 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.74 | -0.27 | -0.39 | -0.44 | 0.13 | -0.18 | Upgrade
|
| EBT Excluding Unusual Items | 19.77 | 83.72 | 195.9 | 140.36 | 127.68 | 196.2 | Upgrade
|
| Gain (Loss) on Sale of Investments | 21.67 | 14.58 | 4.02 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.01 | - | 0.18 | 0.04 | -0.07 | -0.03 | Upgrade
|
| Asset Writedown | -2.14 | -0.11 | -2.58 | -0.66 | -0 | -0.35 | Upgrade
|
| Other Unusual Items | 1.65 | 2.23 | 5.3 | 7.69 | 11.58 | 2.81 | Upgrade
|
| Pretax Income | 40.96 | 100.42 | 202.82 | 147.44 | 139.18 | 198.63 | Upgrade
|
| Income Tax Expense | 3.14 | 8.87 | 26.7 | 21.65 | 17.54 | 30.56 | Upgrade
|
| Earnings From Continuing Operations | 37.82 | 91.55 | 176.12 | 125.79 | 121.65 | 168.07 | Upgrade
|
| Net Income | 37.82 | 91.55 | 176.12 | 125.79 | 121.65 | 168.07 | Upgrade
|
| Net Income to Common | 37.82 | 91.55 | 176.12 | 125.79 | 121.65 | 168.07 | Upgrade
|
| Net Income Growth | -64.41% | -48.02% | 40.01% | 3.41% | -27.62% | 67.59% | Upgrade
|
| Shares Outstanding (Basic) | 418 | 415 | 419 | 415 | 311 | 314 | Upgrade
|
| Shares Outstanding (Diluted) | 418 | 415 | 419 | 415 | 311 | 314 | Upgrade
|
| Shares Change (YoY) | 0.56% | -0.91% | 0.97% | 33.19% | -1.01% | 0.90% | Upgrade
|
| EPS (Basic) | 0.09 | 0.22 | 0.42 | 0.30 | 0.39 | 0.53 | Upgrade
|
| EPS (Diluted) | 0.09 | 0.22 | 0.42 | 0.30 | 0.39 | 0.53 | Upgrade
|
| EPS Growth | -64.61% | -47.54% | 38.66% | -22.36% | -26.88% | 66.10% | Upgrade
|
| Free Cash Flow | -21.61 | -68.36 | -49.47 | 174.84 | 102.92 | 108.28 | Upgrade
|
| Free Cash Flow Per Share | -0.05 | -0.17 | -0.12 | 0.42 | 0.33 | 0.34 | Upgrade
|
| Dividend Per Share | 0.172 | 0.172 | 0.331 | 0.230 | 0.172 | - | Upgrade
|
| Dividend Growth | -47.91% | -47.91% | 43.98% | 33.35% | - | - | Upgrade
|
| Gross Margin | 21.49% | 28.73% | 40.04% | 28.18% | 33.72% | 49.65% | Upgrade
|
| Operating Margin | -0.53% | 6.65% | 21.93% | 14.63% | 21.84% | 33.74% | Upgrade
|
| Profit Margin | 8.78% | 20.53% | 26.56% | 24.43% | 22.50% | 28.35% | Upgrade
|
| Free Cash Flow Margin | -5.02% | -15.33% | -7.46% | 33.96% | 19.04% | 18.26% | Upgrade
|
| EBITDA | 24.64 | 53.68 | 165.63 | 95.73 | 137.43 | 218.24 | Upgrade
|
| EBITDA Margin | 5.72% | 12.04% | 24.98% | 18.59% | 25.42% | 36.81% | Upgrade
|
| D&A For EBITDA | 26.91 | 24.05 | 20.23 | 20.38 | 19.37 | 18.19 | Upgrade
|
| EBIT | -2.26 | 29.64 | 145.4 | 75.35 | 118.06 | 200.05 | Upgrade
|
| EBIT Margin | -0.53% | 6.65% | 21.93% | 14.63% | 21.84% | 33.74% | Upgrade
|
| Effective Tax Rate | 7.66% | 8.83% | 13.16% | 14.68% | 12.60% | 15.38% | Upgrade
|
| Revenue as Reported | 430.77 | 445.86 | 663.03 | 514.91 | 540.62 | 592.92 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.